Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Residual Disease Persistence”

4 trials

Showing 4 of 4 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04062266
What this trial is testing

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Who this might be right for
Acute Myeloid Leukemia in RemissionFLT3 Gene MutationHematologic and Lymphocytic Disorder+3 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Looking for participantsNCT06668558
What this trial is testing

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias 29
Testing effectiveness (Phase 2)Looking for participantsNCT06253650
What this trial is testing

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

Who this might be right for
Gastric CancerHER2-positive Gastric Cancer
Gruppo Oncologico del Nord-Ovest 46
Testing effectiveness (Phase 2)UnknownNCT05031975
What this trial is testing

Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy

Who this might be right for
Colorectal Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 35

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation